Department of Integrative Medicine, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Department of Ultrasound, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Int J Med Sci. 2021 Aug 27;18(15):3599-3608. doi: 10.7150/ijms.62386. eCollection 2021.
The easy liver fibrosis test (eLIFT) is a novel predictor of liver fibrosis in chronic liver disease (CLD). This study aimed to evaluate the predictive value of the eLIFT for liver inflammation and fibrosis in CLD patients. We enrolled 1125 patients with CLD who underwent liver biopsy. The predictive accuracy for liver inflammation and fibrosis of the eLIFT was assessed and compared to that of the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosis-4 score (FIB-4), and gamma-glutamyl transpeptidase-to-platelet ratio (GPR) by ROC (Receiver Operating Characteristic) analysis and decision curve analysis (DCA). The areas under the ROC curves (AUROCs) of the eLIFT for assessing liver inflammation G ≥ 2 and G ≥ 3 were 0.77 (0.75-0.80) and 0.81 (0.79-0.84), with cut-offs of 8.0 and 11.0, respectively. The AUROCs of the eLIFT for predicting fibrosis stages S ≥ 2 and S4 were 0.72 (0.70-0.76) and 0.76 (0.72-0.80), with cut-offs of 9.0 and 10.0, respectively. In discriminating G≥2 inflammation, the AUROC of the eLIFT was better than that of the FIB-4, with no difference compared with the GPR, but lower than that of the APRI. When discriminating G≥3 inflammation, the AUROC of the eLIFT was comparable to that of the APRI and GPR but superior to that of the FIB-4. There were no significant differences between the four indexes for predicting S≥2 and S4. The eLIFT is a potentially useful noninvasive predictor of liver inflammation and fibrosis in patients with CLD.
易肝纤维化检测 (eLIFT) 是一种新型的慢性肝病 (CLD) 肝纤维化预测指标。本研究旨在评估 eLIFT 对 CLD 患者肝炎症和纤维化的预测价值。
我们纳入了 1125 例接受肝活检的 CLD 患者。通过 ROC（Receiver Operating Characteristic）分析和决策曲线分析（DCA）评估 eLIFT 对肝炎症（G≥2 和 G≥3）和纤维化（S≥2 和 S4）的预测准确性，并与天门冬氨酸氨基转移酶与血小板比值指数（APRI）、纤维化-4 评分（FIB-4）和γ-谷氨酰转肽酶与血小板比值（GPR）进行比较。eLIFT 评估肝炎症 G≥2 和 G≥3 的 ROC 曲线下面积（AUROCs）分别为 0.77（0.75-0.80）和 0.81（0.79-0.84），截断值分别为 8.0 和 11.0。eLIFT 预测纤维化分期 S≥2 和 S4 的 AUROCs 分别为 0.72（0.70-0.76）和 0.76（0.72-0.80），截断值分别为 9.0 和 10.0。在区分 G≥2 炎症时，eLIFT 的 AUROC 优于 FIB-4，与 GPR 无差异，但低于 APRI。在区分 G≥3 炎症时，eLIFT 的 AUROC 与 APRI 和 GPR 相当，但优于 FIB-4。四个指标预测 S≥2 和 S4 时无显著差异。
eLIFT 是一种有潜力的用于预测 CLD 患者肝炎症和纤维化的非侵入性指标。
